ESMO 2018 | Dabrafenib/trametinib/pembrolizumab for advanced melanoma: update from KEYNOTE-022
Pembrolizumab is making waves in multiple cancer types, and melanoma is no exception. Here, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, gives us an update on the KEYNOTE-022 trial of dabrafenib and trametinib plus pembrolizumab for BRAF-mutated advanced melanoma (NCT02130466). Dr Ascierto highlights the interesting progression-free survival results and ambitious trial design. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.
Get great new content delivered to your inboxSign up